A new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection — genotype 2 and 3, say a team of scientists. The drug, called sofosbuvir, offers more effective treatment for most patients studied in a Phase 3 clinical trial who had no other treatment options, report researchers.